Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0035078 (renal failure)
 31,970 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

21 patients with severe active lupus nephritis (LN) were treated with intravenous cyclophosphamide monthly doses 0.75 g/m2. The effects were compared with the results obtained in 22 patients by the oral prednisone administration in the dose 1 mg/kg/day. Both groups were not significantly different as regards the initial intensity of the LN symptoms. Complete or partial remission occurred in 17 patients (80.9%) receiving intravenous cyclophosphamide. End-stage renal failure in 2 patients and moderate renal insufficiency in other 2 patients from that group. In the prednisone treated group complete or partial remission was observed in 13 subjects (59.1%). The significant deterioration of the renal function occurred in 9 patients, in 6 into the phase of a moderate renal insufficiency and in 3 patients to the end-stage kidney failure. Additionally, the significant increase of the total serum complement activity and of the plasma platelets count was observed in the cyclophosphamide group, whereas those indicators did not improve in the patients receiving prednisone. The of intravenous pulse cyclophosphamide exhibits an advantage in the treatment of severe proliferative LN.
Pol Arch Med Wewn 1994
PMID:[Monthly intravenous cyclophosphamide in the treatment of lupus nephritis]. 773 2

In 18 patients with acute myocardial infarction admitted to the Cardiological Care Department within 6 hours after the onset of chest pain, before administration of drugs and then in the 2nd, 3rd, 5th and 7th day, the levels of glucose, pyruvate, lactate in venous blood, the lactate/pyruvate ratio (L/P) and pH, actual hydrocarbons, PCO2 and PO2 in capillary arterialized were determined. Depending on the clinical status at admission the patients were classified into 2 groups: I--without complications (I class according to Killip-Kimbal; n = 10), and II--with complications (II-IV class of cardiac failure according to Killip-Kimbal and/or complex ventricular arrhythmias e.i. III-V class according to Lown and heart block of Mobitz--type II and III degree; n = 8). None of the patients had diabetes, chronic respiratory tract diseases, renal failure and liver cirrhosis. The control group consisted of 11 healthy persons. On the first day of myocardial infarction, the significant increase of blood glucose, lactate, pyruvate, as well as significant decrease of blood pH, HCO3- and PO2, and non significant increase of L/P ratio were observed in both groups as compared to the control group. Also there were non significant difference of the glucose, lactate, pyruvate L/P ratio and pH, PCO2 and HCO3- values between the I and II group on the first day of the acute myocardial infarction, with exception of the PO2, which was significantly lower in the group II. In the following days an increase of PO2 was observed. Since this effect coincided with a decrease of lactate concentration (significant only in the group II) it could be concluded, that the observed decrease of the lactate concentration resulted from the higher supply of oxygen. The obtained results have shown, that increase of glycaemia values and decrease of PO2 values may be considered as biochemical markers for hemodynamic complications of acute myocardial infarction.
Pol Arch Med Wewn 1994 Aug
PMID:[Lactate metabolism in acute myocardial infarction]. 780 May 82

Infection caused by Mycobacterium tuberculosis is common among population in Poland. We analyzed the effect of tuberculosis (TB) on patients and graft survival in the group of renal allograft recipients (RAR), treated in our center. Among 1669 renal allograft recipients transplanted from 1981 to 1992, tuberculosis developed in 33 (2%) patients (16 M/17F, age: 22-57 years). The patients were on following immunosuppressive regiments" Pred+Aza+CsA (12 pts), Pred+Aza (12), Pred+CsA (6) and Pred+Aza+CsA+ATG (3). Acute rejection was diagnosed in 27 of them and was treated with methyloprednisone pulses, and in a few cases additionally with ATG (2 pts) or OKT3 (1 pt). In two pts TB had been diagnosed and successfully treated in the past. In 6 pts, on chest X-ray done immediately before transplantation, healed primary lesion (Ghon complex) had been seen. In 16 pts TB developed in the early posttransplant period (median: 3.8 +/- 1.8, range: 1-6 months) and in 17--late after transplantation (median: 31.2 +/- 1.8, range: 13-156 months). In 19 pts symptoms developed soon after treatment of acute rejection. Clinical manifestations include pulmonary TB (30 pts) and extrapulmonary lesions (15 pts): pleural TB (3 pts), miliary TB (5 pts), tuberculous lymphadenitis (1 pt), uveitis (1 pt), renal allograft (2 pts), skeletal (2 pts) and GI tract (1 pt). Diagnosis of TB was made based on clinical presentation and radiologic findings and it was confirmed by positive cultures in 18 pts, by tissue biopsy in 4 pts and by autopsy examination in 9 pts. Treatment regimen included one of the following drug combinations: INH+EMB+RMP (20 pts), INH+RMB+RMP+PZA (10 pts) or INH+EMB+SM (3 pts). Three pts died before TB was recognized and 4 deaths occurred after treatment was started. All these pts developed renal failure. 26 pts were treated for 3-12 months (median, range: 7.8 +/- 2.9) and in 24 of them complete remission was achieved. In this group renal function remained stable in 16 pts and 6 pts developed terminal failure due to chronic rejection. Authors conclude: 1. TB remains a frequent complication in RAR but can be successfully treated when diagnosed early. 2. Extrapulmonary TB is common in RAR. 3. TB deteriorates one year patients (75%) and graft (49%) survivals.
Pneumonol Alergol Pol 1994
PMID:[Tuberculosis in patients after kidney transplantation]. 792 Feb 79

50 patients with terminal renal failure treated with chronic haemodialysis were examined. 24 of them (48%) did not require treatment with erythropoietin (rHuEPO) because of permanent haemoglobin concentration was 9.5 g/dl (5.91 mmol/l) and hematocrite more than 30%. Clinical data of two groups of patients were compared: 1) patients not requiring treatment with rHu EPO, 2) patients requiring treatment with rHu EPO. Attention was paid to the sex, age, the kind of disease which caused renal failure, the duration of dialysotherapy, liver function, HBs antigenemia, presence anti-HCV antibodies, ultrasonographic estimation of patients own kidneys; liver. Patients who did not require treatment with rHu EPO were older, longer treated with chronic haemodialysis and more frequently cysts in their own kidneys were seen. Any significant differences were not observed in both groups of patients as regards their antigenemia HBs or presence of anti HCV-antibodies. The important cardiovascular disease was observed more frequently in patients requiring treatment with rHu EPO.
Pol Arch Med Wewn 1994 Jun
PMID:[Comparison of clinical parameters of chronically hemodialyzed patients not requiring treatment with erythropoietin and patients treated with erythropoietin]. 797 67

In a 45 years woman with advanced nephrotic syndrome in the course of SLE IgM nephropathy, transient renal failure made the continuation of the conventional steroid therapy impossible. Applied as a saving life therapy, plasmapheresis followed by i.v. pulses of cyclophosphamide, caused resolution of lupus nephritis. Since the withdrawal of cyclophosphamide, the patient has been observed for 18 month, showing no evidence of recurrence of lupus nephritis.
Pol Arch Med Wewn 1994 Mar
PMID:[Lupus nephritis with nephrotic syndrome successfully treated with plasmapheresis and cyclophosphamide]. 802 31

MOFS Multi-Organ-Failure-Syndrome has not been recognized until past 10 to 20 years. There are many different causes that may lead to MOFS. Recently it has become clear that MOFS is the clinical endstage of the systemic hypermetabolic response to injury that is heralded by acute lung injury and followed by hepatic and renal failure and often by death. The lung injury may range from relatively slight increase of pulmonary small vessels leakage to the adult respiratory distress syndrome (ARDS). In the first part of the following paper there are presented two clinical cases resulted in MOFS. Pathophysiology, current therapy and prophylaxis of MOFS are reviewed in the second part.
Pneumonol Alergol Pol 1994
PMID:[Multi-organ failure syndrome. Pathophysiology, prevention, treatment]. 806 51

The authors analysed 60 cases of IgA nephropathy diagnosed in biopsy specimens with light microscope examination, immunofluorescence, and electron microscope in 37 patients. It was found that the course of disease was rather mild in the majority of patients and did not accompany renal failure. Examination in light microscope enabled to find disseminated glomerular and mesangial lesions whereas immunofluorescence--potent, granular fluorescence of IgA in mesangium, and sometimes in the walls of vascular loops. Electron microscopic examination revealed dense deposits localized in mesangium and sometimes subendothelially. It is stressed that the diagnosis of IgA nephropathy is possible after exclusion of all pathologies producing IgA deposits in mesangium.
Pol Tyg Lek
PMID:[IgA nephropathy--analysis of 60 cases]. 809 Jun 67

Human recombinant erythropoietin has been administered to 10 children with uremic anaemia in the course of renal failure. Children have been treated with repeated hemodialyses. During a 6-month follow-up, hematocrit and hemoglobin have been 30% and 9-10 g/dL, respectively. An increase in serum uric acid with a decrease in iron levels and transferrin saturation have been noted in all children. No serious adverse reactions have been seen.
Pol Tyg Lek
PMID:[Results of treating uremia anemia with human recombinant erythropoietin]. 809 Jun 64

Thrombotic events sometimes complicate erythropoietin therapy. Fibrinolytic system may play a role in their pathogenesis. The studies were performed on 22 chronically hemodialyzed patients with end-stage renal failure treated with recombinant human erythropoietin (rHuEPO, Eprex, Cilag) for 12 weeks. Alpha 2 antiplasmin (alpha 2AP), antithrombin III (AT III), C1 esterase inhibitor (C1 INH), plasminogen activator inhibitor (PAI) activities, alpha 2macroglobulin (alpha 2M), fibrinogen, fibrin monomers concentration and euglobulin clot lysis time (ECLT) were measured before and after 1, 2, 4, 8 and 12 weeks of rHEPO therapy. A fall in PAI activity (p < 0.05) was found after 1 week, while alpha 2AP and C1 INH activities decreased after 12 weeks of the therapy (p < 0.001 and p < 0.05, respectively). The activity of AT III, the main inhibitor of the coagulation cascade fell after 4 weeks of the treatment with rHuEPO (p < 0.001). Fibrin monomers concentration was found to be decreased after 12 weeks of rHuEPO administration. Fibrinogen and alpha 2M concentration showed no statistically significant changes during rHuEPO therapy. A decrease in plasma fibrinolytic inhibitor activities may be considered as a protective mechanism against thrombotic tendency observed during rHuEPO therapy.
Pol Arch Med Wewn 1993 Oct
PMID:[Erythropoietin and fibrinolysis in uremic patients]. 812 92

Patients with end-stage renal failure (ESRF) have a defect of haemostasis mainly caused by disturbances of platelet vessel wall interactions. An essential part in platelet function is played by the membrane phospholipids. The aim of this study was to estimate phospholipid distribution in platelet membrane and to evaluate the correlation between this distribution and PF3 availability. 18 non-dialysed (group I) and 21 chronically haemodialysed patients (group II) were studied. Phospholipid distribution was determined using TNBS tracer by the Vale method, and by phospholipase hydrolysis according to the modified Chap method. PF3 availability was estimated by the Saleem method. In group I membrane phospholipid distribution was unchanged as compared with control group, in this group decreased PF3 availability was also shown. In group II higher content of phosphatidylserine (PS) and phosphatidylethanolamine (PE) at the outer surface of platelet membrane was observed as compared with the healthy persons. In this group increased PF3 availability correlated with PS and PE exposition was also noted. It may reflects platelet activation in these patients. The different PF3 availability in non-dialysed and chronically haemodialysed patients suggests various pathogenesis of haemostasis disturbances in their patients.
Pol Arch Med Wewn 1993 Dec
PMID:[Distribution of phospholipids in platelet membranes and platelet factor 3 availability in patients with chronic kidney failure]. 814 43


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>